Mirabo Biotechnology - FuturePlay Portfolio Company Details

Mirabo is an Agentic AI platform company that leverages its proprietary AI engine, MiRAiQ, to support the entire antibody drug development lifecycle, from candidate discovery and process development to commercial manufacturing. The company was co-founded by CEO Kyungho Lee, a University of Minnesota alumnus with experience at LG Chem and Sanofi, alongside former WuXi Biologics data scientists and synthetic biology experts from Taiwan and China. Mirabo is headquartered in Hong Kong and operates a subsidiary in Shanghai. Drawing on the founding team’s experience in applying AI to solve complex antibody development and manufacturing challenges at a leading global CDMO, Mirabo develops AI-powered products and solutions for biopharmaceutical development and manufacturing. The company serves a global customer base, including more than 500 pharmaceutical and biotechnology companies in China.